ÖSTROJEN RESEPTÖRÜ NEGATİF İNVAZİV MEME ...

characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer
Res 2004, 10:5367-5374.
41. Fulford G.L, Reis-Filho J.S, Ryder K, Jones C .et al. Basal-like Grade III Invasive
Ductal Carcinoma of the Breast:Patterns of Metastasis and Long-Term
Survival.Breast Cancer Research 2007;9(1)
42. Loakso M, Tanner M,Nilsson J, Wiklund T.Basoluminal carcinoma :A New
Biologically and Prognostically Distinc Entity Between Basal and Luminal Breast
Cancer.Clinical Cancer Research Vol.12,4185-4191,July 15,2006.
43. Kusinska R, Potemski P,JesioneKupnicka D,Kordek R.Immunohistochemical
Identification of basal –type cytokeratins in anvasive ductal breast carcinoma-
Relation with grade, stage,Estrogen Receptor and HER2..Pol J Pathol
2005.56,3,107-110.
44. Kesse –Adu R, Shousha S. Myoepthelial markers are expressed in at least 29% of
oestrogen receptor negative invasive breast carcinoma. Modern pathology
(2004)17, 646-652.
45. Matos I, Dufloth R,Alveranga M,Zeferino L.C ,et al.p63,cytokeratin5,and p-
cadherin: three molecular markers to distinguish basal phenotype in breast
carcinomas. Virchows Arch(2005) 447:668-694.
46. Filho.R.S.J,Simpson.T.P,Gale.T,Lakhani.S.R.The molecular genetics of breast
cancer: The contribution of comparative genomic hybridization. Pathology-
Research and practice 201(2005)713-725.
47. Pinilla.S.M,Honrado.E,Hardisson D.Caveolin1 expression is assocated with a basal
like phenotype in sporadic and hereditary breast cancer.Breast cancer Research and
Treatment (2006) 99:85-90
48. Simpson T.P, Filho.R.S, Gale T,Lakhani S.R.Molecular evalution of breast
cancer.J.Pathol 2005;205:248-254.
78